Peptide Atlas · Peptide

IGF-1 (Mecasermin / recombinant human IGF-1)

Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007.

established

provisional
2 citations
0 discussions
0 followers
IGF-I
Increlex
Mecasermin
Somatomedin C
rhIGF-1

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for IGF-1 (Mecasermin / recombinant human IGF-1). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Mecasermin safety and preliminary efficacy in Rett syndrome (phase 1)	emerging	pmid 24623853
Mecasermin for severe primary IGF-1 deficiency: regulatory approval and long-term use	established	pmid 19707272

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.